by Jason | Jan 21, 2021 | Industry News
Expert perspectives in ulcerative colitis: An interview with Dr Peter Irving Ulcerative colitis (UC) is a debilitating inflammatory bowel disease (IBD) affecting approximately 1 in 250 people in the UK.1 Galapagos UK Medical Advisor, Claire Hamilton spoke with Dr...
by Jason | Jan 21, 2021 | Industry News
We are Galapagos UK: The unknown is our comfort zone. Who we are We are Galapagos, a pioneering biotechnology company, founded in Belgium in 1999 by our CEO Onno van de Stolpe, focused on discovering and developing innovative medicines to improve peoples’ lives. We...
by Jason | Jan 21, 2021 | Industry News
Looking to the future in inflammatory bowel disease (IBD) care: Perspectives from Professor Charlie Lees Professor Charlie Lees is a Consultant Gastroenterologist in the Edinburgh IBD Unit, and Professor of Gastroenterology at the University of Edinburgh. He will be...
by Jason | Jan 11, 2021 | Industry News
Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust Dr. Ajay Verma, consultant gastroenterologist and physician, and Anusha Patel, regional homecare lead pharmacist...
by Jason | Jan 11, 2021 | Industry News
Tillotts LOGIC Education is an educational programme for gastrointestinal healthcare professionals, organised and funded by Tillotts, as part of our commitment to reinvest in the NHS. We provide award winning educational initiatives, including fully funded modules to...
Recent Comments